GlassScriptPhysician profile
Juan S Solis
NPI 1316943178
$6,197.77
in general payments reported to CMS, 2019-2025
30 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $608 · 2021: $671 · 2022: $1,073 · 2023: $675 · 2024: $1,055 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,076 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,076.45 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,435.59 | 2019-2025 | Ubrelvy, Linzess, Vraylar |
| Novo Nordisk INC | $1,168.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $620.87 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $374.98 | 2019-2025 | Otezla, Repatha, Prolia |
| Allergan, INC. | $330.05 | 2019-2020 | |
| Astellas Pharma US INC | $302.99 | 2019-2025 | Veozah |
| Lilly USA, LLC | $225.72 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $217.80 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $162.13 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $146.90 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.51 | 2021-2025 | Xifaxan |
| Horizon Therapeutics Plc | $133.65 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $133.58 | 2024-2025 | Zenpep |
| Exact Sciences Corporation | $114.86 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $112.53 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $79.42 | 2025 | Auvelity |
| Dexcom, INC. | $76.16 | 2022-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $63.54 | 2022-2025 | Freestyle Libre 2 |
| Upsher-Smith Laboratories LLC | $55.75 | 2022 | |
| Lundbeck LLC | $54.54 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $54.11 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.75 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.78 | 2022 | |
| Janssen Pharmaceuticals, INC | $29.68 | 2019 | |
| Glaxosmithkline, LLC. | $17.18 | 2025 | Shingrix, Arexvy |
| Corcept Therapeutics | $16.67 | 2025 | Korlym |
| Amarin Pharma, INC. | $14.03 | 2020 | |
| Merck Sharp & Dohme LLC | $12.45 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.82 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Solis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.